Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District

Detalhes bibliográficos
Autor(a) principal: Meira, Kaic Leite
Data de Publicação: 2024
Outros Autores: Santos, Raissa Pereira, Silva, Lorena Silveira da, Gonçalves, Hugo Carvalho Barros, Siqueira, Fabio
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista JRG de Estudos Acadêmicos
Texto Completo: http://revistajrg.com/index.php/jrg/article/view/919
Resumo: Breast cancer is a group of diseases with a high incidence in the Brazilian population and its treatment involves the use of cardiotoxic antineoplastics. This work aims to analyze cardiotoxicity in patients with human epidermal growth factor receptor type 2 breast cancer undergoing treatment with trastuzumab at the oncology outpatient clinic of the Hospital Regional de Taguatinga – Federal District, through a cross-sectional study in the period between January from 2022 to December 2022, using the Left Ventricular Ejection Fraction values ​​before and during antineoplastic treatment. In addition, information such as age, comorbidities and harmful habits were also verified to create a profile of the patients. 34 patients were included in the research, all of whom were female, with a predominance of age under 60 years and brown/yellow color/race. Regarding clinical characteristics, the majority of patients did not have other comorbidities and did not use new lifestyle habits, with only three having a reduction in the value of the Left Ventricular Ejection Fraction ≥ 16% and among these, two with lower values to 55%. In general, breast cancer treatment can result in cardiotoxicity, and this adverse effect is present in patients undergoing treatment at the Taguatinga Regional Hospital.
id JRG_b0c28ee7f5826280772bf06e0e74efc8
oai_identifier_str oai:ojs2.revistajrg.com:article/919
network_acronym_str JRG
network_name_str Revista JRG de Estudos Acadêmicos
repository_id_str
spelling Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal DistrictAvaliação da cardiotoxicidade em pacientes com câncer de mama em tratamento com trastuzumabe em uma unidade de oncologia do Distrito FederalNeoplasias da MamaReceptor HER2 TrastuzumabeBreast NeoplasmsReceptor, HER2 TrastuzumabBreast cancer is a group of diseases with a high incidence in the Brazilian population and its treatment involves the use of cardiotoxic antineoplastics. This work aims to analyze cardiotoxicity in patients with human epidermal growth factor receptor type 2 breast cancer undergoing treatment with trastuzumab at the oncology outpatient clinic of the Hospital Regional de Taguatinga – Federal District, through a cross-sectional study in the period between January from 2022 to December 2022, using the Left Ventricular Ejection Fraction values ​​before and during antineoplastic treatment. In addition, information such as age, comorbidities and harmful habits were also verified to create a profile of the patients. 34 patients were included in the research, all of whom were female, with a predominance of age under 60 years and brown/yellow color/race. Regarding clinical characteristics, the majority of patients did not have other comorbidities and did not use new lifestyle habits, with only three having a reduction in the value of the Left Ventricular Ejection Fraction ≥ 16% and among these, two with lower values to 55%. In general, breast cancer treatment can result in cardiotoxicity, and this adverse effect is present in patients undergoing treatment at the Taguatinga Regional Hospital.O câncer de mama é um conjunto de doenças com elevada incidência na população brasileira e no seu tratamento há a utilização de antineoplásicos cardiotóxicos. Este trabalho tem como objetivo desse analisar a cardiotoxicidade em pacientes com câncer de mama receptor tipo 2 do fator de crescimento epidérmico humanoem tratamento com trastuzumabe no ambulatório de oncologia do Hospital Regional de Taguatinga – Distrito Federal,por meio de um estudo transversal no período entre janeiro de 2022 a dezembro de 2022, utilizando os valores da Fração de Ejeção do Ventrículo Esquerdo  antes e durante o tratamento antineoplásico. Além disso, também foram verificadas informações como idade, comorbidades e hábitos nocivos para traçar um perfil dos pacientes. 34 pacientes foram incluídos na pesquisa, sendo em sua totalidade do sexo feminino, com predomínio de idade inferior a 60 anos e cor/raça parda/amarela. Com relação as características clinicas, a maioria das pacientes não possuíam outras comorbidades e nem fazia uso de hábitos noviços de vida, sendo que apenas três tiveram redução do valor da Fração de Ejeção do Ventrículo Esquerdo ≥ 16% e dentre estas, duas com valores inferiores a 55%. De maneira geral, o tratamento do câncer de mama pode resultar em cardiotoxicidade, sendo este efeito adverso presente nas pacientes em tratamento no Hospital Regional de Taguatinga.Editora JRG2024-01-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo avaliado pelos Paresapplication/pdfhttp://revistajrg.com/index.php/jrg/article/view/91910.55892/jrg.v7i14.919ark:/57118/JRG.v7i14.919JRG Journal of Academic Studies; Vol. 7 No. 14 (2024): JRG Journal of Academic Studies; e14919JRG Journal of Academic Studies ; Vol. 7 Núm. 14 (2024): Revista JRG de Estudos Acadêmicos; e14919JRG Journal of Academic Studies; V. 7 N. 14 (2024): Revista JRG de Estudos Acadêmicos; e14919Revista JRG de Estudos Acadêmicos ; v. 7 n. 14 (2024): Revista JRG de Estudos Acadêmicos; e149192595-1661ark:/57118/jrg.v7i14reponame:Revista JRG de Estudos Acadêmicosinstname:Editora JRGinstacron:JRGporhttp://revistajrg.com/index.php/jrg/article/view/919/816https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMeira, Kaic LeiteSantos, Raissa PereiraSilva, Lorena Silveira daGonçalves, Hugo Carvalho BarrosSiqueira, Fabio2024-01-26T01:19:49Zoai:ojs2.revistajrg.com:article/919Revistahttp://revistajrg.com/index.php/jrgPRIhttp://revistajrg.com/index.php/jrg/oaiprofessorjonas@gmail.com||2595-16612595-1661opendoar:2024-01-26T01:19:49Revista JRG de Estudos Acadêmicos - Editora JRGfalse
dc.title.none.fl_str_mv Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
Avaliação da cardiotoxicidade em pacientes com câncer de mama em tratamento com trastuzumabe em uma unidade de oncologia do Distrito Federal
title Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
spellingShingle Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
Meira, Kaic Leite
Neoplasias da Mama
Receptor HER2
Trastuzumabe
Breast Neoplasms
Receptor, HER2
Trastuzumab
title_short Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
title_full Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
title_fullStr Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
title_full_unstemmed Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
title_sort Assessment of cardiotoxicity in patients with breast cancer undergoing treatment with trastuzumab in an oncology unit in the Federal District
author Meira, Kaic Leite
author_facet Meira, Kaic Leite
Santos, Raissa Pereira
Silva, Lorena Silveira da
Gonçalves, Hugo Carvalho Barros
Siqueira, Fabio
author_role author
author2 Santos, Raissa Pereira
Silva, Lorena Silveira da
Gonçalves, Hugo Carvalho Barros
Siqueira, Fabio
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Meira, Kaic Leite
Santos, Raissa Pereira
Silva, Lorena Silveira da
Gonçalves, Hugo Carvalho Barros
Siqueira, Fabio
dc.subject.por.fl_str_mv Neoplasias da Mama
Receptor HER2
Trastuzumabe
Breast Neoplasms
Receptor, HER2
Trastuzumab
topic Neoplasias da Mama
Receptor HER2
Trastuzumabe
Breast Neoplasms
Receptor, HER2
Trastuzumab
description Breast cancer is a group of diseases with a high incidence in the Brazilian population and its treatment involves the use of cardiotoxic antineoplastics. This work aims to analyze cardiotoxicity in patients with human epidermal growth factor receptor type 2 breast cancer undergoing treatment with trastuzumab at the oncology outpatient clinic of the Hospital Regional de Taguatinga – Federal District, through a cross-sectional study in the period between January from 2022 to December 2022, using the Left Ventricular Ejection Fraction values ​​before and during antineoplastic treatment. In addition, information such as age, comorbidities and harmful habits were also verified to create a profile of the patients. 34 patients were included in the research, all of whom were female, with a predominance of age under 60 years and brown/yellow color/race. Regarding clinical characteristics, the majority of patients did not have other comorbidities and did not use new lifestyle habits, with only three having a reduction in the value of the Left Ventricular Ejection Fraction ≥ 16% and among these, two with lower values to 55%. In general, breast cancer treatment can result in cardiotoxicity, and this adverse effect is present in patients undergoing treatment at the Taguatinga Regional Hospital.
publishDate 2024
dc.date.none.fl_str_mv 2024-01-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigo avaliado pelos Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://revistajrg.com/index.php/jrg/article/view/919
10.55892/jrg.v7i14.919
ark:/57118/JRG.v7i14.919
url http://revistajrg.com/index.php/jrg/article/view/919
identifier_str_mv 10.55892/jrg.v7i14.919
ark:/57118/JRG.v7i14.919
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv http://revistajrg.com/index.php/jrg/article/view/919/816
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Editora JRG
publisher.none.fl_str_mv Editora JRG
dc.source.none.fl_str_mv JRG Journal of Academic Studies; Vol. 7 No. 14 (2024): JRG Journal of Academic Studies; e14919
JRG Journal of Academic Studies ; Vol. 7 Núm. 14 (2024): Revista JRG de Estudos Acadêmicos; e14919
JRG Journal of Academic Studies; V. 7 N. 14 (2024): Revista JRG de Estudos Acadêmicos; e14919
Revista JRG de Estudos Acadêmicos ; v. 7 n. 14 (2024): Revista JRG de Estudos Acadêmicos; e14919
2595-1661
ark:/57118/jrg.v7i14
reponame:Revista JRG de Estudos Acadêmicos
instname:Editora JRG
instacron:JRG
instname_str Editora JRG
instacron_str JRG
institution JRG
reponame_str Revista JRG de Estudos Acadêmicos
collection Revista JRG de Estudos Acadêmicos
repository.name.fl_str_mv Revista JRG de Estudos Acadêmicos - Editora JRG
repository.mail.fl_str_mv professorjonas@gmail.com||
_version_ 1797068982869557248

Registros relacionados